ReadingResearchRadarInvestment framework
Sign in / Sign up
← Back to reading
NewsMaterial3 min readDisconfirmAI Editorial

Janus Henderson Portfolio Manager Daniel Lyons: Biotech Pullback is Technical Deleveraging, Not Fundamental Deterioration

Janus Henderson Portfolio Manager Daniel Lyons argues that the sharp decline in the biotechnology sector following the 2026 U.S. midterm elections was concentrated in AI-linked genomics and life science tools companies, driven by deleveraging and technical factors rather than a deterioration in industry fundamentals. Unlike the widespread valuation bubbles seen post-2021, current overvaluations are confined to a narrow group; most companies with validated platforms, commercial products, and late-stage assets still trade at attractive valuations. On the policy front, he believes the impact of a Democratic victory is more nuanced than the initial market reaction suggested, with expanded healthcare coverage potentially supporting utilization, while significant changes to the drug pricing framework appear unlikely.

2026-11-10 00:01 GMT+8

In remarks published on November 9, 2026, Janus Henderson Portfolio Manager Daniel Lyons stated that the sharp sell-off in the biotechnology sector following the midterm elections should not be interpreted as a deterioration in fundamental conditions. His core assessment is that this pullback is the result of broader deleveraging dynamics and technical factors, with the steepest declines concentrated in genomics, diagnostics, and life science tools companies whose valuations had been pushed higher by enthusiasm for artificial intelligence (AI), rather than indicating a fundamental turning point across the entire biotechnology industry.

Lyons pointed out that surging interest in AI-enabled drug development and personalized medicine over recent months created a clear divergence in valuations within the sector. AI-linked life science tools stocks rallied sharply through September, while many traditional biotechnology companies—including those advancing promising new therapies—continued to trade at attractive valuations. He believes the volatility since early October may help investors refocus on fundamentals and identify attractive entry points into these high-quality biotechnology companies.

Sign in / Sign up
ReadingResearchRadarInvestment framework

This assessment rests on a historical comparison. Lyons notes that while the biotechnology sector’s strong performance over the past year might evoke memories of the speculative froth preceding the 2021 downturn, today’s landscape features several key differences. Having endured the post-pandemic drawdown and tighter financing conditions associated with the Federal Reserve’s aggressive rate-hike cycle in 2022–2023, he views biotechnology as a healthier, more disciplined sector: many companies now possess stronger balance sheets, more experienced management teams, and a greater number of commercial-stage assets than they did a few years ago. Furthermore, whereas the boom of 2020–2021 was broad-based, current valuation excesses are largely concentrated in a relatively narrow group of companies.

On the policy front, Lyons argues that the implications of a comprehensive Democratic sweep in the midterm elections for healthcare are more subtle—and potentially more benign—than the initial market reaction suggested. He assesses that Democrats are more likely to shift their policy agenda toward expanding healthcare coverage and protecting existing benefits, rather than pursuing new drug-pricing legislation. Specifically, the enhanced Affordable Care Act (ACA) premium subsidies, which expired at the end of 2025, are expected to be a priority for restoration. Meanwhile, debates regarding Medicaid are primarily focused on federal work requirements that could lead to coverage losses. Increased stability in coverage could provide incremental support for overall healthcare utilization and patient volumes.

For the medical technology (medtech) sector, Lyons sees this as a potential positive factor, given that the sector has previously operated in a challenging environment marked by strained hospital budgets and coverage losses, pushing valuations to historically depressed levels. Regarding biopharmaceuticals, he believes Democrats are more likely to defend existing Medicare drug-price negotiation provisions enacted under the Inflation Reduction Act rather than push for new legislation. This could offer some reassurance to pharmaceutical and biotechnology companies, as policy uncertainty surrounding drug pricing had previously periodically weighed on valuations.

Lyons explicitly acknowledges that it is too early to determine how a Democratic-led Congress will interact with the Trump Administration or what will ultimately translate into concrete healthcare policy. Drug pricing will remain a political focal point, but he considers the likelihood of significant changes within the current framework to be low. His conclusion is that healthcare continues to offer a combination of long-term structural drivers (medical innovation and demographic aging) and defensive characteristics, alongside diversified return sources beyond the AI theme. Recent volatility may serve to redirect investor attention toward valuation opportunities.

Sources

  • janushenderson.comUS Advisor↗
Continue researching →